Robert M. Cannon, MD

Clinical Insights

Liver-Directed Therapies for Transplant-Eligible and Near Transplant-Eligible Patients With Hepatocellular Carcinoma: An Institutional Approach

08/04/2020

Robert M. Cannon , MD;

Majd Habash , BS;

Souheil Saddekni , MD;

Andrew J. Gunn , MD;

In this article, we will discuss our approach to liver-directed therapies for transplant-eligible and near transplant-eligible patients at the University of Alabama in Birmingham, Alabama.

In this article, we will...

08/04/2020

IO Learning

Clinical Images

Transarterial Chemoembolization as a Mechanism to Downstage Patients With Hepatocellular Carcinoma to Transplant Eligibility

10/20/2021

Bryan Wright , BS ;

Robert M. Cannon , MD;

Andrew J. Gunn , MD;

A 63-year-old man diagnosed with HCC was deemed an appropriate liver transplant candidate, but currently outside Milan criteria. He was referred to IR for consideration of TACE as a mechanism to downstage the patient into transplant...

A 63-year-old man diagnosed with...

10/20/2021

IO Learning